Lung Adenocarcinoma

Oncology·MeSH: Adenocarcinoma of Lung

Prevalence

30.0 / 100K

9 drugs in development·4 companies·12 clinical trials

Drug Pipeline by Phase

Phase 2(4)

Drug	Company
Methoxyamine	ADMA BIOLOGICS, INC. (ADMA)
Methoxyamine	ENANTA PHARMACEUTICALS INC (ENTA)
Methoxyamine	Merus N.V. (MRUS)
QL1706	ENANTA PHARMACEUTICALS INC (ENTA)

Phase 1(1)

Drug	Company
Pemetrexed	ADMA BIOLOGICS, INC. (ADMA)

Phase 4(4)

Drug	Company
Baxdrostat and dapagliflozin	Travere Therapeutics, Inc. (TVTX)
Dapagliflozin along with standard medical therapy	Travere Therapeutics, Inc. (TVTX)
Dapagliflozin Propanediol	Travere Therapeutics, Inc. (TVTX)
Zibotentan/Dapagliflozin FDC	Travere Therapeutics, Inc. (TVTX)

BioSniper tracks 9 drugs in development for Lung Adenocarcinoma across 4 companies.

There are 12 clinical trials targeting Lung Adenocarcinoma tracked by BioSniper.

The estimated prevalence of Lung Adenocarcinoma is approximately 30.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.